These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32078234)

  • 1. Optimization of hepatitis C virus screening strategies by birth cohort in Italy.
    Kondili LA; Gamkrelidze I; Blach S; Marcellusi A; Galli M; Petta S; Puoti M; Vella S; Razavi H; Craxi A; Mennini FS;
    Liver Int; 2020 Jul; 40(7):1545-1555. PubMed ID: 32078234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
    Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
    BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
    Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
    Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.
    Rein DB; Smith BD; Wittenborn JS; Lesesne SB; Wagner LD; Roblin DW; Patel N; Ward JW; Weinbaum CM
    Ann Intern Med; 2012 Feb; 156(4):263-70. PubMed ID: 22056542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Universal screening and treatment towards the elimination of chronic hepatitis C in China: an economic evaluation.
    Fang K; Wang HL; Lin Y; Zheng L; Li S; Wu J
    Public Health; 2024 Mar; 228():186-193. PubMed ID: 38387115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Microsimulation Study of the Cost-Effectiveness of Hepatitis C Virus Screening Frequencies in Hemodialysis Centers.
    Epstein RL; Pramanick T; Baptiste D; Buzzee B; Reese PP; Linas BP; Sawinski D
    J Am Soc Nephrol; 2023 Feb; 34(2):205-219. PubMed ID: 36735375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness and budget impact analysis of facility-based screening and treatment of hepatitis C in Punjab state of India.
    Chugh Y; Premkumar M; Grover GS; Dhiman RK; Teerawattananon Y; Prinja S
    BMJ Open; 2021 Feb; 11(2):e042280. PubMed ID: 33589457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation.
    Marcellusi A; Mennini FS; Ruf M; Galli C; Aghemo A; Brunetto MR; Babudieri S; Craxi A; Andreoni M; Kondili LA
    Liver Int; 2022 Jan; 42(1):26-37. PubMed ID: 34582627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling the Impact and Cost-effectiveness of Extended Hepatitis C Virus Screening and Treatment with Direct-acting Antivirals in a Swiss Custodial Setting.
    Girardin F; Hearmon N; Castro E; Negro F; Eddowes L; Gétaz L; Wolff H
    Clin Infect Dis; 2019 Nov; 69(11):1980-1986. PubMed ID: 30715266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Another Step Toward Hepatitis C Elimination: An Economic Evaluation of an Irish National Birth Cohort Testing Program.
    Carty PG; Teljeur C; De Gascun CF; Gillespie P; Harrington P; McCormick A; O'Neill M; Smith SM; Ryan M
    Value Health; 2022 Dec; 25(12):1947-1957. PubMed ID: 35778325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens.
    Eckman MH; Ward JW; Sherman KE
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):930-939.e9. PubMed ID: 30201597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost-effectiveness of HCV testing strategies for hepatitis C elimination in general population in China].
    Liu PC; Xu D; Ding GW; Zhao L; Yu JJ; Liu ZF; Li J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2024 Mar; 45(3):464-472. PubMed ID: 38514325
    [No Abstract]   [Full Text] [Related]  

  • 13. A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective.
    Kim HL; Kim KA; Choi GH; Jang ES; Ki M; Choi HY; Jeong SH
    Clin Mol Hepatol; 2022 Jan; 28(1):91-104. PubMed ID: 34736311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
    Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
    Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
    Blach S; Schaetti C; Bruggmann P; Negro F; Razavi H
    Swiss Med Wkly; 2019 Mar; 149():w20026. PubMed ID: 30905063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eradicating hepatitis C: Are novel screening strategies for people who inject drugs cost-effective?
    Manca F; Robinson E; Dillon JF; Boyd KA
    Int J Drug Policy; 2020 Aug; 82():102811. PubMed ID: 32585583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
    Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
    Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the cost-effectiveness of hepatitis C screening strategies in France.
    Deuffic-Burban S; Huneau A; Verleene A; Brouard C; Pillonel J; Le Strat Y; Cossais S; Roudot-Thoraval F; Canva V; Mathurin P; Dhumeaux D; Yazdanpanah Y
    J Hepatol; 2018 Oct; 69(4):785-792. PubMed ID: 30227916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.
    McEwan P; Ward T; Yuan Y; Kim R; L'italien G
    Hepatology; 2013 Jul; 58(1):54-64. PubMed ID: 23389841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.